News
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,
Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
In this week’s edition of InnovationRx, we look at Moderna’s use of quantum computers, a new top drug regulator at the FDA, ...
The FDA on Tuesday rejected a skin therapy from Replimune Group, suggesting a hardened stance on drug approvals under new ...
A decline in the expression of the epigenetic regulator Setd8 in neural stem cells (NSCs) during early adulthood leads to chromatin condensation and reduced gene expression, suppressing NSC ...
News-Medical.Net on MSN13d
Egr-1 gene identified as crucial regulator of regulatory T cells in multiple sclerosis
Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect ...
The UK’s drugs regulator has introduced new regulations that will enable hospitals to perform the final manufacturing steps of personalised gene therapy treatments. The Medicines and Healthcare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback